F
Filip K. Knop
Researcher at University of Copenhagen
Publications - 523
Citations - 17834
Filip K. Knop is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 61, co-authored 437 publications receiving 13614 citations. Previous affiliations of Filip K. Knop include Copenhagen University Hospital & Victor Chang Cardiac Research Institute.
Papers
More filters
Journal ArticleDOI
Extrapancreatic glucagon: Present status.
TL;DR: New data on extrapancreatic glucagon secretion is reviewed in the context of historical data and recent analytical breakthroughs, and the source, regulation and potential physiological role of extrapancy glucagon are discussed and ongoing challenges and knowledge-gaps are outlined.
Journal ArticleDOI
Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control
Maria Luisa Fernandez-Cachon,Søren L. Pedersen,Kristoffer T. G. Rigbolt,Chen Zhang,Katrine Fabricius,Henrik H. Hansen,Lisbeth Elster,Lisbeth N Fink,Matthias Schäfer,Nicolai Rhee,Ebbe Langholz,Erik Wandall,Steffen U. Friis,Peter Vilmann,Viggo B. Kristiansen,Christina Schmidt,Kay Schreiter,Kristin Breitschopf,Thomas Hübschle,Tina Jorsal,Tina Vilsbøll,Thorsten Schmidt,Stefan Theis,Filip K. Knop,Philip J. Larsen,Jacob Jelsing +25 more
TL;DR: GN and UGN, as well as their prohormones, do not seem to play a significant role in body weight regulation and glycemic control, suggesting that guanylin‐family peptides do not show promise as targets for the treatment of obesity or diabetes.
Journal ArticleDOI
Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young.
Signe Harring Østoft,Jonatan I. Bagger,Torben Hansen,Bolette Hartmann,Oluf Pedersen,Jens J. Holst,Filip K. Knop,Tina Vilsbøll +7 more
TL;DR: The pathophysiology of MODY3 includes exaggerated postprandial glucagon responses and increased fasting DPP4 enzymatic activity but normal postpr andial incretin responses both in patients with MODY2 and in patients in matched healthy individuals.
Journal ArticleDOI
Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study
Thomas F. Dejgaard,Filip K. Knop,Lise Tarnow,Christian Seerup Frandsen,T. Hansen,Thomas Almdal,Jens J. Holst,Sten Madsbad,Henrik U. Andersen +8 more
TL;DR: A protocol is described for a study evaluating the efficacy and safety of adding a GLP-1RA to insulin treatment in overweight patients with T1D in a randomised, double-blinded, controlled design.
Journal ArticleDOI
Use of exenatide and liraglutide in Denmark: a drug utilization study
Anton Pottegård,Bine Kjøller Bjerregaard,Michael Larsen,Kasper Søltoft Larsen,Jesper Hallas,Filip K. Knop,Søren Ilsøe Moreno +6 more
TL;DR: The preferred GLP-1 analogues in Denmark is liraglutide and exenatide, and certain aspects of the utilization of these analogues, such as large regional differences and concomitant use ofGLP- 1 analogues and insulin, warrant further investigation.